<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255918</url>
  </required_header>
  <id_info>
    <org_study_id>03-0857</org_study_id>
    <secondary_id>R01MH061412</secondary_id>
    <secondary_id>DNBBS MC-R</secondary_id>
    <nct_id>NCT00255918</nct_id>
  </id_info>
  <brief_title>Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients</brief_title>
  <official_title>Phase 1 Trial of 3-2,4 Dimethoxbenzylidene Anabaseine in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the effectiveness of a drug, dimethoxbenzylidene anabaseine, in
      producing beneficial effects similar to that of nicotine in individuals with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia is a chronic and severe brain disorder that can significantly impact quality of
      life. It is characterized by delusions, paranoia, and disordered thinking. The cause of
      schizophrenia has not yet been determined. However, there are many treatments, including drug
      therapy and cognitive behavioral therapy, that may help to alleviate symptoms of the
      condition. Nicotinic receptors are involved in a number of biological processes; they are
      numerous throughout the central and peripheral nervous systems and are diverse in structure
      and expression. Genetic and neurobiological research has identified decreased expression of
      the a7 nicotinic receptor as an element in schizophrenia that is related to poor psychosocial
      outcome. Data indicate that drug therapy may reduce this deficit in receptor expression.
      Nicotine has been found to stimulate the a7 nicotinic receptor; however, the physiological
      dependence associated with nicotine makes it an undesirable option. Dimethoxbenzylidene
      anabaseine (DMXB-A) can stimulate the a7 nicotinic receptor; its advantages include easy oral
      administration and the lack of dependence-causing effects. This study will determine whether
      DMXB-A can safely and effectively stimulate the a7 nicotinic receptor in schizophrenia
      patients and reduce their neurobiological symptoms.

      This study will last 6 weeks. Participants will have study visits each week for the duration
      of the study. During each visit, participants will be randomly assigned to receive either
      DMXB-A or placebo. An electrocardiogram (EKG) will measure the heart function of participants
      and participants' blood pressure will be measured. After the first dose of either DMXB-A or
      placebo, participants will receive a second dose 2 hours later. An evoked potential test,
      which measures the brain's response to stimuli, will be performed after both doses.
      Neuropsychological tests, such as verbal reasoning and visual retention, will be performed
      following the second dose of either DMXB-A or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Scale Score for the Repeatable Battery for the Assessment of Neuropsychological Status</measure>
    <time_frame>Measured at 2 hours after drug or placebo</time_frame>
    <description>ten subtests which give five scores, one for each of the five domains tested (immediate memory, visuospatial/constructional, language, attention, delayed memory).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Psychiatric Rating Scale</measure>
    <time_frame>Measured 4 hours after drug or placebo administration</time_frame>
    <description>Brief Psychiatric Rating Scale (BPRS) is a rating scale used to measure psychiatric symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P50 auditory evoked potential test amplitude/conditioning amplitude ratio</measure>
    <time_frame>Measured 2.5 hours after drug or placebo administration</time_frame>
    <description>The evoked response amplitude measured in mV to the initial auditory stimulus which is compared to the evoked response amplitude which is measured in mV to a second auditory stimulus that occurs 500 ms later.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Psychotic Disorders</condition>
  <arm_group>
    <arm_group_label>Dimethoxybenzylidene anabaseine 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take active experimental medication (Dimethoxybenzylidene anabaseine (DMXB-A) 75 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dimethoxybenzylidene anabaseine 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take active experimental medication (Dimethoxybenzylidene anabaseine (DMXB-A) 150 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimethoxybenzylidene anabaseine (DMXB-A)</intervention_name>
    <description>DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose</description>
    <arm_group_label>Dimethoxybenzylidene anabaseine 75 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Dimethoxybenzylidene anabaseine 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo dosed to match active medication</description>
    <arm_group_label>Dimethoxybenzylidene anabaseine 75 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Dimethoxybenzylidene anabaseine 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimethoxybenzylidene anabaseine (DMXB-A)</intervention_name>
    <description>DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose</description>
    <arm_group_label>Dimethoxybenzylidene anabaseine 75 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Dimethoxybenzylidene anabaseine 150 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia

        Exclusion Criteria:

          -  History of cardiovascular illness or neurological illness other than schizophrenia

          -  Current substance abuse, including nicotine

          -  History of clozapine use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Freedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado General Clinical Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Martin LF, Kem WR, Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl). 2004 Jun;174(1):54-64. Epub 2004 Feb 19. Review.</citation>
    <PMID>15205879</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2005</study_first_submitted>
  <study_first_submitted_qc>November 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <last_update_submitted>June 30, 2015</last_update_submitted>
  <last_update_submitted_qc>June 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Evoked Potentials</keyword>
  <keyword>3-(2,4-dimethoxybenzylidene)anabaseine</keyword>
  <keyword>DMXB-A</keyword>
  <keyword>Receptors, Nicotinic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3-(2,4-dimethoxybenzylidene)anabaseine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

